Epoetin alfa
| Clinical data | |
|---|---|
| Pronunciation | /ɛˈpoʊ.ɪtɪn/ |
| Trade names | Epogen |
| Biosimilars | epoetin alfa-epbx, Abseamed,[1][2] Binocrit,[3] Epoetin Alfa Hexal,[4] Retacrit[5][6] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a692034 |
| License data |
|
| Routes of administration | Intravenous, subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C815H1317N233O241S5 |
| Molar mass | 18396.19 g·mol−1 |
| (what is this?) (verify) | |
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology.[7][8] Epoetin alfa is an erythropoiesis-stimulating agent.[7] It stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin alfa is developed by Amgen.[7]
It is on the World Health Organization's List of Essential Medicines.[9] It was approved for medical use in the European Union in August 2007,
- ^ Cite error: The named reference
Abseamed EPARwas invoked but never defined (see the help page). - ^ "Abseamed". Union Register of medicinal products. Retrieved 14 January 2021.
- ^ Cite error: The named reference
Binocrit EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Epoetin Alfa Hexal EPARwas invoked but never defined (see the help page). - ^ "Retacrit- epoetin alfa-epbx injection, solution". DailyMed. 29 January 2020.
- ^ "Retacrit- epoetin alfa-epbx injection, solution". DailyMed. 26 June 2024. Retrieved 25 July 2024.
- ^ a b c d "Epogen- epoetin alfa solution". DailyMed. 25 July 2018.
- ^ Walsh G, Spada S (2005). "Epogen/Procrit". Directory of approved biopharmaceutical products. Boca Raton: CRC Press. pp. 39–41. ISBN 978-0-415-26368-9.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.